No Data
E-miniangu-B (01541.HK) plans to allocate a total of 33.15 million new H-shares, with a total fundraising of 0.234 billion Hong Kong dollars.
KeLongHui November 21st | Yiming Ounc-B (01541.HK) issued an announcement. On November 21, 2024, the company entered into a placing agreement with China International Capital Corporation (as the placing agent). According to this, the placing agent has agreed to act as the company's exclusive placing agent and will endeavor to persuade subscribers to subscribe for a total of 33.15 million new H shares at a placing price of HK$7.05 per share in accordance with the terms set out in the placing agreement and subject to the conditions set out in such agreement. The placing shares represent approximately 8.86% and 9.50% of the company's issued share capital and total issued H shares as of the date of this announcement, and of the shares issued
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Placing of New H Shares
Yiming Enke-B (01541.HK) announced positive clinical trial results for IMM0306 combined with lenalidomide treatment for chronic lymphoma.
Gelonghui, November 18 - Yiming Anke-B (01541.HK) announced that the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has recruited a total of 27 evaluable patients (25 patients with follicular lymphoma (FL) and two patients with marginal zone lymphoma (MZL)) as of October 26, 2024. The following figure illustrates the efficacy data for patients with relapsed or refractory (R/R) FL as of October 26, 2024: as of October 26, 2024, the overall response rate in 25 evaluable R/R FL patients is...
Express News | Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Eli Lilly and Company (01541.HK) has initiated a phase II clinical trial of IMM27M for the treatment of estrogen receptor-positive (ER+) advanced breast cancer that has failed endocrine therapy or recurred.
Kanghui November 13th 丨 Yimingangke-B (01541.HK) announced that the company has initiated Phase II clinical trials for IMM27M therapy for estrogen receptor-positive (ER+) advanced breast cancer after endocrine therapy failure or relapse, and has recruited the first patient. In addition, the IMM27M Phase I dose escalation study was completed at the end of 2023, with the following results (as of August 6, 2024): In the Phase I trial, a total of eight evaluable ER+ advanced or metastatic breast cancer patients were recruited. Among them, two achieved partial response (PR) and four patients had stable disease (SD), overall.
HK Stock Market | Yimingangke-B (01541) opened more than 4% higher, the core product IMM01 III clinical trial completed the first patient dosing.
Yiming Angke-B (01541) opened over 4% higher, as of the time of writing, up 4.19%, priced at 9.7 Hong Kong dollars, with a transaction amount of 3.4551 million Hong Kong dollars.
No Data
No Data